Arch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ARTH
CUSIPN/A
Phone617-431-2313
Debt
Debt-to-Equity RatioN/A
Current Ratio18.77
Quick Ratio18.77
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book41.70
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-7,780,000.00
Net MarginsN/A
Return on Equity-254.30%
Return on Assets-115.86%
Miscellaneous
Employees10
Outstanding Shares159,820,000
Market Cap$62.33 million
Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions
What is Arch Therapeutics' stock symbol?
Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."
How were Arch Therapeutics' earnings last quarter?
Arch Therapeutics Inc (OTCMKTS:ARTH) released its earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.01) EPS for the quarter, hitting analysts' consensus estimates of ($0.01). View Arch Therapeutics' Earnings History.
When is Arch Therapeutics' next earnings date?
What price target have analysts set for ARTH?
3 equities research analysts have issued 12 month target prices for Arch Therapeutics' stock. Their forecasts range from $3.00 to $3.00. On average, they expect Arch Therapeutics' share price to reach $3.00 in the next year. This suggests a possible upside of 640.7% from the stock's current price. View Analyst Price Targets for Arch Therapeutics.
What is the consensus analysts' recommendation for Arch Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arch Therapeutics.
Who are some of Arch Therapeutics' key competitors?
Some companies that are related to Arch Therapeutics include Liquidia Technologies (LQDA), Endologix (ELGX), SeaSpine (SPNE), RenovaCare (RCAR), Apollo Endosurgery (APEN), Alphatec (ATEC), Sensus Healthcare (SRTS), Invuity (IVTY), Motus GI (MOTS), Invo Bioscience (IVOB), Neovasc (NVCN), CAS Medical Systems (CASM), Spectral Medical (EDTXF), Restoration Robotics (HAIR) and iCAD (ICAD).
Who are Arch Therapeutics' key executives?
Arch Therapeutics' management team includes the folowing people:
- Dr. Terrence W. Norchi, Co-Founder, Pres, CEO, Sec. & Director (Age 53)
- Mr. Richard E. Davis, Chief Financial Officer and Treasurer (Age 60)
- Dr. Avtar S. Dhillon, Bus. Advisor (Age 57)
- Mr. Rutledge Ellis-Behnke, Co-Founder & Scientific Advisor
- Dr. Steven A. Kates Ph.D., VP of Technology
Has Arch Therapeutics been receiving favorable news coverage?
News headlines about ARTH stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Arch Therapeutics earned a daily sentiment score of 0.15 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.97 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Arch Therapeutics.
How do I buy shares of Arch Therapeutics?
Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arch Therapeutics' stock price today?
One share of ARTH stock can currently be purchased for approximately $0.4050.
How big of a company is Arch Therapeutics?
Arch Therapeutics has a market capitalization of $62.33 million. Arch Therapeutics employs 10 workers across the globe.
How can I contact Arch Therapeutics?
Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected]
MarketBeat Community Rating for Arch Therapeutics (OTCMKTS ARTH)
MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe ARTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
